Tesamorelin (Egrifta)

Tesamorelin is a real, regulated drug with clinical trial data behind its approved use, available only by prescription. This page describes its approved use and standard prescribing information for that specific, narrow indication — that's public medical information about a regulated drug, not personalized medical advice, and not a basis for off-label use. Talk to your doctor about whether it's appropriate for you.

Tesamorelin is a synthetic analog of GHRH (growth hormone-releasing hormone). Like CJC-1295 and sermorelin, it works through the body's own pituitary feedback loop — binding GHRH receptors to stimulate the pituitary gland's own growth hormone release, rather than supplying growth hormone directly. What distinguishes it from those compounds is that it's the one member of this mechanism class that has actually been taken through full FDA drug review and approved, for a specific medical indication.

The FDA approved tesamorelin, under the brand name Egrifta, on November 10, 2010 — the first approved treatment for lipodystrophy. Its approval is specifically for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, a fat-redistribution condition associated with antiretroviral therapy. Approval was based on two clinical trials in 816 HIV-infected adults, which showed statistically significant reductions in visceral abdominal fat versus placebo. A newer, more concentrated formulation (Egrifta WR / F8) was later approved for the same indication. Tesamorelin is not approved for general anti-aging, muscle-gain, or fitness use in people without HIV-associated lipodystrophy — that would be an off-label use outside what its trials actually studied.

FierceBiotech — FDA Approves Egrifta →

Egrifta is dosed as a once-daily subcutaneous injection, with the specific dose and injection site rotation set by a prescriber as part of managing HIV-associated lipodystrophy. This is general public prescribing information about an approved indication, not a personalized recommendation — your prescriber sets your actual dose and confirms the diagnosis it's approved for.

CJC-1295 works through essentially the same GHRH-receptor mechanism as tesamorelin, but has never been through FDA drug review for any indication. Tesamorelin is the approved version of this mechanism, for a narrow indication — it shows what happens when this mechanism actually gets studied in large controlled trials and approved, for a specific disease population, at a specific dose, with a specific safety record. That approval doesn't transfer to CJC-1295 or extend to unstudied, off-label fitness use of tesamorelin itself.

Reported side effects include injection-site reactions, joint pain, swelling (peripheral edema), and muscle pain. Because it raises IGF-1, it carries precautions around active malignancy, and it's not recommended for anyone with disruption of the pituitary-hypothalamic axis, pregnancy, or hypersensitivity to GHRH analogs. As with other GH-axis compounds, there's a theoretical concern about effects on glucose metabolism.

Managed Healthcare Executive — FDA Approves Tesamorelin for HIV Patients with Lipodystrophy